血液透析患者血管钙化的发病机制及治疗进展  

Pathogenesis and Treatment Progress of Vascular Calcification in Patients with Hemodialysis

作　　者：李雪芹[1] 高雪 罗燕[1] 张华[1] 龙燕琼 LI Xueqin;GAO Xue;LUO Yan;ZHANG Hua;LONG Yanqiong(Department of Nephrology,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院肾脏内科,成都610041

出　　处：《医学综述》2023年第7期1372-1376,1383,共6页Medical Recapitulate

摘　　要：维持性血液透析(MHD)是终末期肾病(ESRD)患者肾脏代替治疗的有效方法,随着血液净化技术及其他治疗方法的完善,MHD患者的生存率明显提高,但心血管疾病(CVD)的发生率仍很高。血管钙化是ESRD患者常见的血管病变,因血管壁上出现大量钙盐沉积所致,血管钙化极大增加了MHD患者心血管疾病的发病率及死亡率。目前,血管钙化的病机尚未完全明确,临床上缺乏预防血管钙化的有效措施,因此研究血管钙化的发病机制有助于防治CVD。Maintenance hemodialysis(MHD)is an effective method of renal replacement therapy for patients with end-stage renal disease(ESRD).With the improvement of blood purification technology and other treatment methods,the survival rate of patients with MHD is significantly improved,but the incidence rates of cardiovascular disease(CVD)are still high.Vascular calcification is a common vascular disease of ESRD patients,which is caused by a large amount of calcium salt deposition on the vascular wall,greatly increasing the incidence of CVD and mortality rate of the patients with MHD.At present,the pathogenesis of vascular calcification is not fully clear,and there is a lack of effective measures to prevent vascular calcification in clinical practice.Therefore,studying the pathogenesis of vascular calcification is helpful to prevent and treat CVD.

关 键 词：肾脏疾病 血液透析 血管钙化 钙磷代谢 血管平滑肌细胞 

分 类 号：R459.5[医药卫生—治疗学]